Tirzepatide pen reference · FDA prescribing information

Mounjaro KwikPen Click & Dose Chart

All 6 Mounjaro (tirzepatide) single-dose KwikPen strengths with pen colors, the FDA-label titration schedule, storage requirements, and step-by-step injection instructions. Use the “What pen am I on?” finder to see your current pen by treatment week.

Mounjaro KwikPen Strengths

6 single-dose pens. Each pen delivers one fixed dose — tap a pen for details.

How the titration schedule works

The Mounjaro FDA prescribing information [1] specifies a fixed titration protocol: start at 2.5 mg once weekly for 4 weeks, then increase to 5 mg once weekly. After at least 4 weeks on any dose, the prescriber may increase in 2.5 mg increments based on clinical response. The maximum recommended dose is 15 mg once weekly.

Each KwikPen is a single-dose, pre-filled autoinjector. You use one pen per injection, then discard it. There is no “click counting” for multi-dose selection — the pen delivers its entire fixed dose in a single injection.

Pen colors

Each pen strength has a distinct color label per the FDA-approved labeling [1][2]. This color-coding helps prevent dose mix-ups when patients have multiple pens:

  • 2.5 mg: Yellow
  • 5 mg: Reddish-brown (maroon)
  • 7.5 mg: Green
  • 10 mg: Dark blue
  • 12.5 mg: Purple
  • 15 mg: Blue-gray

Storage

Per the FDA prescribing information [1]: store Mounjaro in the refrigerator at 36°F to 46°F (2°C to 8°C). May be stored at room temperature (up to 86°F / 30°C) for up to 21 days. Do not freeze. Do not use if the pen has been frozen. Protect from light.

Administration

Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each injection. Do not inject into areas where the skin is tender, bruised, red, or hard [1][2].

Important disclaimer

This tool is for educational reference only and does not constitute medical advice. Dose changes should only be made under the direction of your prescribing clinician. Always follow the instructions provided with your specific pen. If you are unsure which pen to use, contact your prescriber or pharmacist.

Related tools and research

References

  1. 1.Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use — US Prescribing Information. Highlights of prescribing information, dosage forms/strengths, dosage and administration, storage and handling. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
  2. 2.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — Instructions for Use: Single-Dose Pen. FDA Approved Labeling (IFU). 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
  3. 3.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  4. 4.Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PMID: 34170647.